Drug Profile
Research programme: mucosal-penetrating aciclovir - KALA BIO
Alternative Names: Aciclovir-MPPLatest Information Update: 04 Aug 2023
Price :
$50
*
At a glance
- Originator Kala Pharmaceuticals
- Developer KALA BIO
- Class Hypoxanthines
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 02 Aug 2023 Kala Pharmaceuticals is now called KALA BIO
- 11 Aug 2022 Discontinued - Preclinical for Herpes simplex virus infections (Prevention) in USA (Vaginal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections(Prevention) in USA (Vaginal)